Scientists at East China Normal University, East China University of Science & Technology, Jinfeng Laboratory and Zhengzhou University have identified ribosomal protein S6 kinase α-6 (RPS6KA6; RSK-4) inhibitors reported to be useful for the treatment of cancer.